ClinicalTrials.gg
RecruitingNCT07029828B7981028Updated Oct 15, 2026

A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.

A Phase 3 interventional study of Ritlecitinib higher dose and Ritlecitinib lower dose in Severe Alopecia Areata, sponsored by Pfizer. Recruiting at 67 sites in 9 countries. Open to participants aged 6 Years to 14 Years. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.
Updated Oct 15, 2026First sites in Italy, Spain and United KingdomSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
6 Years to 14 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies in Alopecia Areata by Pfizer — 4 open to participants now, 8 under way, 4 of them phase 3. Alopecia Areata · Pfizer.

Planned enrollment
7th of 10
140 · median 175
Started
2025
with 5 others
Phase 3
5 of 17
3 open now
Registered
11th of 17
by date

Among the 17 studies in Alopecia Areata by Pfizer, this one is the 7th largest by planned enrollment of the 10 interventional ones that give a count, is one of 6 that started in 2025, is one of 5 in phase 3, and was the 11th registered.

Alopecia Areata

220 studies on the registry are indexed under Alopecia Areata; 61 are open to participants now.

Browse Alopecia Areata studies →

Open to participants now

4 of the 17 studies in Alopecia Areata by Pfizer are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 41 Alopecia Areata studies recruiting now, 16 (39%) set no upper age limit and 21 (51%) stop at 75 or younger; 20 take children under 18; 5 take healthy volunteers.

This study: 6 Years to 14 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Alopecia Areata by Pfizer, or all of them as a file.
02

Study summary

The purpose of this clinical trial is to learn about long-term safety and long-term effects of the study medicine (called ritlecitinib) for the potential treatment of severe alopecia areata, a condition that causes hair loss.

This study is seeking participants who have:

  • previously completed one of Pfizer's pediatric studies for Alopecia Areata (B7981027 or B7981031).
  • at least 50% scalp hair loss due to alopecia areata (for participants enrolling from the study B7981031).
  • received varicella vaccination (2 doses) or have been infected by varicella zoster virus before based on blood test reports.

All participants in this study will receive the study medicine (ritlecitinib). Participants who received ritlecitinib higher or lower doses in the parent Study B7981027 will continue receiving the same ritlecitinib dose in this trial.

Participants who received placebo in the parent Study B7981027 and all participants from parent Study B7981031 will receive either higher or lower dose of ritlecitinib in this trial.

The study medicine is a capsule that is taken by mouth. It is taken 1 time each day at home.

The study will help see if ritlecitinib is safe and effective. Participants will take part in this study for a duration of up to 3 years (36 months). During this time, they will have 17 study visits at the study clinic. The study team will also call participants once a month over the phone.

Read the detailed description

Study B7981028 is a Phase 3 long-term, double-blind extension study to evaluate the safety and efficacy of ritlecitinib in participants with severe alopecia areata (AA) who have completed previous ritlecitinib studies B7981031 or B7981027 and are eligible to enroll for B7981028 study.

The primary objective of this study is to evaluate the long-term safety and tolerability of ritlecitinib in pediatric participants with severe AA who have completed the studies B7981027 or B7981031. The secondary objectives of this study are to evaluate the long-term efficacy of ritlecitinib, durability of response and effect of ritlecitinib on patient centered outcomes.

All participants in this study will receive ritlecitinib higher or lower dose for up to an additional 3 years following completion of either of the prior parent studies. Participants who received higher or lower doses in the parent Study B7981027 will continue receiving the same ritlecitinib dose in Study B7981028. Participants who received placebo in the parent Study B7981027 and all participants from parent Study B7981031 will be randomized at a 1:1 ratio to receive higher or lower dose of ritlecitinib in Study B7981028.

At least 140 participants evaluable for primary analysis will be enrolled in Study B7981028.

Participants will be evaluated for treatment continuation criteria at Months 3 and 6 (for those who were previously assigned to active treatment in parent Study B7981027) and at Months 9 and 12 in Study B7981028 (for those who previously completed Study B7981031 or were assigned to placebo in the parent Study B7981027). Ritlecitinib treatment will be discontinued for any participant who does not meet the study treatment continuation criteria.

Safety monitoring will be performed to identify and monitor the known and potential risks of ritlecitinib.

The efficacy assessments include Severity of Alopecia Tool (SALT), eyebrow and eyelash assessments. Patient reported outcomes including Patient's Global Impression of Change (PGI-C), Patient-Reported Outcomes Measurement Information System (PROMIS) Parent Proxy - Anxiety Short Form 8a and Depressive Symptoms Short Form 6a, Behavior Rating Inventory of Executive Function®, Second Edition (BRIEF®2), and modified Children's Dermatology Life Quality Index (CDLQI) will be assessed throughout the study.

03

Conditions studied

  • Severe Alopecia Areata

Browse trials for

Keywords

  • Alopecia Areata
  • Children
  • Ritlecitinib
  • Long-term extension study
04

Who can participate

Ages eligible
6 Years to 14 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants with alopecia areata (AA) (including alopecia totalis [AT] and alopecia universalis [AU]) who completed the studies B7981027 or B7981031.
  2. For participants originating from Study B7981031: At least 50% scalp hair loss due to AA (ie, a SALT score of ≥50) at both the Screening and Baseline visits.

Exclusion criteria

Exclusion Criteria:

  1. Exclusion criteria for participants originating from Study B7981027 with ≤ 30 Days between last dose in Study B7981027 and first visit of Study B7981028

    1. During Study B7981027 or in the period between the last dose of study intervention in Study B7981027 and the first dose of study intervention of Study B7981028, presence of safety events that would require permanent discontinuation based on the B7981028 protocol.
    2. Study participants discontinued from Study B7981027 due to issues other than safety-related events and considered by the investigator for enrolment in Study B7981028 must have resolution of the issue(s) resulting in discontinuation from the parent study prior to enrolment in Study B7981028.
  2. Exclusion criteria for participants originating from Study B7981031 or from Study B7981027 with >30 Days between last dose in Study B7981027 and first visit of Study B7981028

    1. During Study B7981031 or Study B7981027 or in the period between the last dose of study intervention in Study B7981031 or Study B7981027 and the first dose of study intervention of Study B7981028, presence of safety events that would require permanent discontinuation based on the B7981028 protocol.
    2. Any present or history of malignancies or lymphoproliferative disorders.
    3. Evidence of untreated or inadequately treated active or latent Mycobacterium tuberculosis (TB) infection, history (one or more episodes) of severe or serious cytomegalovirus (CMV), herpes zoster (shingles) or disseminated herpes simplex, infection with virus (HBV) or virus (HCV).

      -

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
140 participants (estimated)

Study arms

  • Experimental
    Ritlecitinib higher dose

    Participants will receive 1 ritlecitinib higher dose capsule once a day (QD) and 1 placebo lower dose capsule QD orally for up to 3 years. Participants who meet the protocol-defined treatment discontinuation criteria based on not achieving the required efficacy threshold will be switched to placebo but will remain in the study. Those participants will receive 1 placebo higher dose capsule QD and 1 placebo lower dose capsule QD.

    Drug: Ritlecitinib higher dose

  • Experimental
    Ritlecitinib lower dose

    Participants will receive 1 ritlecitinib lower dose capsule once a day (QD) and 1 placebo higher dose capsule QD orally for up to 3 years. Participants who meet the protocol-defined treatment discontinuation criteria based on not achieving the required efficacy threshold will be switched to placebo but will remain in the study. Those participants will receive 1 placebo higher dose capsule QD and 1 placebo lower dose capsule QD.

    Drug: Ritlecitinib lower dose

Interventions

  • DrugRitlecitinib higher dose

    Study intervention will be provided as oral capsules centrally by the sponsor in HDPE bottles.

  • DrugRitlecitinib lower dose

    Study intervention will be provided as oral capsules centrally by the sponsor in HDPE bottles.

06

What researchers measure

Primary outcomes

  1. Incidence of treatment-emergent adverse events (AEs).

    Time frame: From the time participant signs informed consent/assent, through and including a minimum of 28 calendar days after the last administration of the study intervention (up to approximately 3 years).

  2. Incidence of Serious Adverse Events (SAEs) and AEs leading to permanent discontinuation from the study.

    Time frame: From the time participant signs informed consent/assent, through and including a minimum of 28 calendar days after the last administration of the study intervention (up to approximately 3 years).

Secondary outcomes

  1. Proportion of participants achieving absolute Severity of Alopecia Tool (SALT) score ≤10.

    Time frame: Months 3,6,9,12,15,18,21,24,27,30,33 and 36.

  2. Proportion of participants achieving absolute SALT score ≤20.

    Time frame: Months 3,6,9,12,15,18,21,24,27,30,33 and 36.

  3. Change from baseline (CFB) in SALT score.

    Time frame: Baseline, Months 3,6,9,12,15,18,21,24,27,30,33 and 36.

  4. Proportion of participants achieving at least 2 grade improvement or a score of 3 in eyebrow assessment (EBA) score in participants with an abnormal EBA at baseline.

    Time frame: Months 3,6,9,12,15,18,21,24,27,30,33 and 36.

  5. Proportion of participants achieving at least 2 grade improvement or a score of 3 in eyelash assessment (ELA) score in participants with an abnormal ELA at baseline.

    Time frame: Months 3,6,9,12,15,18,21,24,27,30,33 and 36.

  6. Proportion of participants achieving Patient Global Impression of Change (PGI-C) response defined as a score of "moderately improved" or "greatly improved".

    Time frame: Months 3,6,9,12,15,18,21,24,27,30,33 and 36.

  7. CFB in PROMIS Parent Proxy Anxiety Symptoms T-score.

    Time frame: Baseline, Months 3,6,9,12,15,18,21,24,27,30,33 and 36.

  8. CFB in Behavior Rating Inventory of Executive Function (BRIEF®2) T-scores for the 3 index scores (Behavior Regulation Index (BRI), Emotion Regulation Index (ERI), Cognitive Regulation Index (CRI)).

    Time frame: Baseline, Months 3,6,9,12,15,18,21,24,27,30,33 and 36.

  9. CFB in modified Children's Dermatology Life Quality Index (CDLQI) total score.

    Time frame: Baseline, Months 3,6,9,12,15,18,21,24,27,30,33 and 36.

  10. CFB in Wechsler Intelligence Scale for Children® Fifth Edition (WISC-V).

    Time frame: Baseline, Month 36

Other outcomes

  1. CFB in Patient-Reported Outcomes Measurement Information System (PROMIS) Parent Proxy Depressive Symptoms T-score.

    Time frame: Baseline, Months 3,6,9,12,15,18,21,24,27,30,33 and 36.

07

Study locations

56 of 67 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Jun 2030, 57 months after the start.

Of 20 phase 3 interventional studies under Alopecia Areata, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 46. This study's planned 57 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2025
First posted
Jun 19, 2025
StartActual
Sep 10, 2025
Primary completionEst.
Jun 26, 2030
CompletionEst.
Jun 26, 2030
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
35 sites added, 9 sites removed — first sites in Italy, Spain and United Kingdom. 17 sites changed recruiting status (17 now recruiting)
Show 17 sites
  • Michigan Dermatology Institute · Waterford, United StatesNot yet recruiting→Recruiting
  • Penn State Health Milton S. Hershey Medical Center · Hershey, United StatesNot yet recruiting→Recruiting
  • Hospices Civils de Lyon - Hopital Femme Mere Enfant · Bron, FranceNot yet recruiting→Recruiting
  • CHU de Dijon Bourgogne · Dijon, FranceNot yet recruiting→Recruiting
  • GHICL - Service d'investigation - Recherche clinique · Lille, FranceNot yet recruiting→Recruiting
  • Hôpital Saint Vincent de Paul · Lille, FranceNot yet recruiting→Recruiting
  • Tohoku University Hospital · Sendai, JapanNot yet recruiting→Recruiting
  • Kyorin University Hospital · Mitaka, JapanNot yet recruiting→Recruiting
  • Cityclinic Przychodnia Lekarsko-Psychologiczna Matusiak Spółka Partnerska · Wroclaw, PolandNot yet recruiting→Recruiting
  • DERMEDIC Iwona Zdybska · Lublin, PolandNot yet recruiting→Recruiting
  • Klinika Osipowicz & Turkowski · Warsaw, PolandNot yet recruiting→Recruiting
  • Provita Poliklinika · Warsaw, PolandNot yet recruiting→Recruiting
  • Klinika Ambroziak Dermatologia · Warsaw, PolandNot yet recruiting→Recruiting
  • Royalderm Agnieszka Nawrocka · Warsaw, PolandNot yet recruiting→Recruiting
  • Centrum Medyczne Angelius Provita · Katowice, PolandNot yet recruiting→Recruiting
  • Uniwersytecki Szpital kliniczny im. F. Chopina w Rzeszowie · Rzeszów, PolandNot yet recruiting→Recruiting
  • Dermoklinika - Centrum Medyczne spółka cywilna M. Kierstan, J. Narbutt, A. Lesiak · Lodz, PolandNot yet recruiting→Recruiting
Show 35 added (11 United States, 9 China, 4 United Kingdom, 3 Czechia, 2 Italy, 2 Japan, 2 Spain, 1 France, 1 Poland)
  • University of California~ Irvine · Irvine, United States
  • Southern California Clinical Research · Santa Ana, United States
  • Children's Hospital Colorado · Aurora, United States
  • Children's National Hospital · Washington D.C., United States
  • Endeavor Health Clinical Operations · Skokie, United States
  • Medical University of South Carolina - South Carolina Translational Research Nexus Clinic · Charleston, United States
  • Dell Children's Medical Center · Austin, United States
  • Driscoll Children's Hospital · Corpus Christi, United States
  • Austin Institute for Clinical Research · Pflugerville, United States
  • Children's Wisconsin · Milwaukee, United States
  • Medical College of Wisconsin · Milwaukee, United States
  • China-Japan Friendship Hospital · Beijing, China
  • Beijing Children's hospital, Capital Medical University · Beijing, China
  • Beijing Tongren Hospital affiliated to Capital Medical University · Beijing, China
  • Beijing Tongren Hospital affiliated to Capital Medical University · Beijing, China
  • The First Affiliated Hospital of Guangzhou Medical University · Guangzhou, China
  • Hunan Children's Hospital · Changsha, China
  • Chengdu Women and Children Center Hospital · Chengdu, China
  • The First People's Hospital of Hangzhou · Hangzhou, China
  • Hangzhou Third Hospital · Hangzhou, China
  • Fakultní Nemocnice Brno · Brno, Czechia
  • Fakultni Nemocnice Plzen · Pilsen, Czechia
  • Fakultni nemocnice Bulovka · Praha 8 - Libeň, Czechia
  • Hospices Civils de Lyon - CIC - Hopital Louis Pradel · Bron, France
  • IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico S: Orsola · Bologna, Italy
  • Asst Spedali Civili Di Brescia · Brescia, Italy
  • Niigata University Medical & Dental Hospital · Niigata, Japan
  • Osaka Metropolitan University Hospital · Osaka, Japan
  • Specjalistyczny Gabinet Dermatologiczny Aplikacyjno-Badawczy, Marek Brzewski, Paweł Brzewski s.c. · Krakow, Poland
  • Hospital Universitario Miguel Servet · Zaragoza, Spain
  • …and 5 more on the registry record
Show 9 removed
  • California Dermatology & Clinical Research Institute · Encinitas, United States
  • D&H Tamarac Research Center · Tamarac, United States
  • Complete Behavior Health (Dr. Brittany Marshall, Licensed Psychologist) · Papillion, United States
  • Regents of the University of New Mexico · Albuquerque, United States
  • Equity Medical, LLC · The Bronx, United States
  • Medical University of South Carolina Department of Dermatology and Dermatologic Surgery · Charleston, United States
  • Hôpitaux Drôme Nord · Romans-sur-Isère, France
  • Osaka Metropolitan University Hospital · Osaka, Japan
  • Państwowy Instytut Medyczny MSWiA · Warsaw, Poland
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    35 sites added, 9 sites removed — first sites in Italy, Spain and United Kingdom. 17 sites changed recruiting status (17 now recruiting)
    Show 17 sites
    • Michigan Dermatology Institute · Waterford, United StatesNot yet recruiting→Recruiting
    • Penn State Health Milton S. Hershey Medical Center · Hershey, United StatesNot yet recruiting→Recruiting
    • Hospices Civils de Lyon - Hopital Femme Mere Enfant · Bron, FranceNot yet recruiting→Recruiting
    • CHU de Dijon Bourgogne · Dijon, FranceNot yet recruiting→Recruiting
    • GHICL - Service d'investigation - Recherche clinique · Lille, FranceNot yet recruiting→Recruiting
    • Hôpital Saint Vincent de Paul · Lille, FranceNot yet recruiting→Recruiting
    • Tohoku University Hospital · Sendai, JapanNot yet recruiting→Recruiting
    • Kyorin University Hospital · Mitaka, JapanNot yet recruiting→Recruiting
    • Cityclinic Przychodnia Lekarsko-Psychologiczna Matusiak Spółka Partnerska · Wroclaw, PolandNot yet recruiting→Recruiting
    • DERMEDIC Iwona Zdybska · Lublin, PolandNot yet recruiting→Recruiting
    • Klinika Osipowicz & Turkowski · Warsaw, PolandNot yet recruiting→Recruiting
    • Provita Poliklinika · Warsaw, PolandNot yet recruiting→Recruiting
    • Klinika Ambroziak Dermatologia · Warsaw, PolandNot yet recruiting→Recruiting
    • Royalderm Agnieszka Nawrocka · Warsaw, PolandNot yet recruiting→Recruiting
    • Centrum Medyczne Angelius Provita · Katowice, PolandNot yet recruiting→Recruiting
    • Uniwersytecki Szpital kliniczny im. F. Chopina w Rzeszowie · Rzeszów, PolandNot yet recruiting→Recruiting
    • Dermoklinika - Centrum Medyczne spółka cywilna M. Kierstan, J. Narbutt, A. Lesiak · Lodz, PolandNot yet recruiting→Recruiting
    Show 35 added (11 United States, 9 China, 4 United Kingdom, 3 Czechia, 2 Italy, 2 Japan, 2 Spain, 1 France, 1 Poland)
    • University of California~ Irvine · Irvine, United States
    • Southern California Clinical Research · Santa Ana, United States
    • Children's Hospital Colorado · Aurora, United States
    • Children's National Hospital · Washington D.C., United States
    • Endeavor Health Clinical Operations · Skokie, United States
    • Medical University of South Carolina - South Carolina Translational Research Nexus Clinic · Charleston, United States
    • Dell Children's Medical Center · Austin, United States
    • Driscoll Children's Hospital · Corpus Christi, United States
    • Austin Institute for Clinical Research · Pflugerville, United States
    • Children's Wisconsin · Milwaukee, United States
    • Medical College of Wisconsin · Milwaukee, United States
    • China-Japan Friendship Hospital · Beijing, China
    • Beijing Children's hospital, Capital Medical University · Beijing, China
    • Beijing Tongren Hospital affiliated to Capital Medical University · Beijing, China
    • Beijing Tongren Hospital affiliated to Capital Medical University · Beijing, China
    • The First Affiliated Hospital of Guangzhou Medical University · Guangzhou, China
    • Hunan Children's Hospital · Changsha, China
    • Chengdu Women and Children Center Hospital · Chengdu, China
    • The First People's Hospital of Hangzhou · Hangzhou, China
    • Hangzhou Third Hospital · Hangzhou, China
    • Fakultní Nemocnice Brno · Brno, Czechia
    • Fakultni Nemocnice Plzen · Pilsen, Czechia
    • Fakultni nemocnice Bulovka · Praha 8 - Libeň, Czechia
    • Hospices Civils de Lyon - CIC - Hopital Louis Pradel · Bron, France
    • IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico S: Orsola · Bologna, Italy
    • Asst Spedali Civili Di Brescia · Brescia, Italy
    • Niigata University Medical & Dental Hospital · Niigata, Japan
    • Osaka Metropolitan University Hospital · Osaka, Japan
    • Specjalistyczny Gabinet Dermatologiczny Aplikacyjno-Badawczy, Marek Brzewski, Paweł Brzewski s.c. · Krakow, Poland
    • Hospital Universitario Miguel Servet · Zaragoza, Spain
    • …and 5 more on the registry record
    Show 9 removed
    • California Dermatology & Clinical Research Institute · Encinitas, United States
    • D&H Tamarac Research Center · Tamarac, United States
    • Complete Behavior Health (Dr. Brittany Marshall, Licensed Psychologist) · Papillion, United States
    • Regents of the University of New Mexico · Albuquerque, United States
    • Equity Medical, LLC · The Bronx, United States
    • Medical University of South Carolina Department of Dermatology and Dermatologic Surgery · Charleston, United States
    • Hôpitaux Drôme Nord · Romans-sur-Isère, France
    • Osaka Metropolitan University Hospital · Osaka, Japan
    • Państwowy Instytut Medyczny MSWiA · Warsaw, Poland
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07029828
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jun 19, 2025
Start date
Sep 10, 2025
Primary completion
Jun 26, 2030 (estimated)
Completion
Jun 26, 2030 (estimated)
Last update
Oct 15, 2026

Study contacts

Pfizer CT.gov Call Center
Contact
ClinicalTrials.gov_Inquiries@pfizer.com
1-800-718-1021
Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion